Effects of chemotherapy during pregnancy on the maternal and fetal heart

Prenatal Diagnosis

Volumn 32, Issue 7, 2012, Pages 614-619

  Gziri, Mina Mhallem ^a   Amant, Frédéric ^a   Debiève, Frédéric ^b   Van Calsteren, Kristel ^a   De Catte, Luc ^a   Mertens, Luc ^c,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CYTARABINE; DOCETAXEL; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; FETUS HEART; FETUS OUTCOME; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; NEOPLASM; PERICARDITIS; PREGNANCY; PREMATURE LABOR; PRENATAL EXPOSURE; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; REVIEW; THROMBOPHLEBITIS; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARDIOTOXINS; FEMALE; FETAL DISEASES; FETAL HEART; HEART; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 84863427352     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.3847     Document Type: Review

References (51)

1. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009;27(1):45-51.
2. Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 2010;16(1):76-82.
3. Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol 2010;33(3):221-8.
4. Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 2010;28(4):683-9.
5. Daniilidis A, Giannoulis C, Sardeli C, Dinas K, Nasioutziki M, Tantanasis T, et al. Pregnancy-associated breast cancer--a review analysis. Eur J Gynaecol Oncol 2010;31(5):485-90.
6. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004;5(5):283-91.
7. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol 2010;28(8):1276-81.
8. Albini A, Pennesi G, Donatelli F, Cammarota R, De FS, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102(1):14-25.
9. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8(8):1039-58.
10. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26(22):3777-84.
11. Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 2006;57:485-98.
12. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53(24):2231-47.
13. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 2010;53(2):105-13.
14. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007;7(2):114-21.
15. Minotti G, Mancuso C, Frustaci A, Mordente A, Santini SA, Calafiore AM, et al. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. J Clin Invest 1996;98(3):650-61.
16. Lebrecht D, Walker UA. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 2007;7(2):108-13.
17. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 2007;23(1):15-25.
18. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010;121(2):276-92.
19. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999;20(6):421-8.
20. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97(11):2869-79.
21. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
22. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27(34):5838-47.
23. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25(23):3525-33.
24. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008;31(6):459-67.
25. Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf 2010;9(2):335-46.
26. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010;7(10):564-75.
27. Van Calsteren K, Verbesselt R, Ottevanger N, Halaska M, Heyns L, Van Bree R, et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand 2010;89(10):1338-45.
28. Grohard P, Akbaraly JP, Saux MC, Gimenez S, Robert J, Brachet-Liermain A, et al. Transplacental passage of doxorubicin. J Gynecol Obstet Biol Reprod (Paris) 1989;18(5):595-600.
29. Gaillard B, Leng JJ, Grellet J, Ducint D, Saux MC. Transplacental passage of epirubicin. J Gynecol Obstet Biol Reprod (Paris) 1995;24(1):63-8.
30. Van Calsteren K, Verbesselt R, Beijnen J, Devlieger R, De Catte L, Chai DC, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol 2010;119(3):594-600.
31. Marnitz S, Kohler C, Oppelt P, Schmittel A, Favero G, Hasenbein K, et al. Cisplatin application in pregnancy: first in vivo analysis of 7 patients. Oncology 2010;79(1-2):72-7.
32. Paskulin GA, Gazzola Zen PR, de Camargo Pinto LL, Rosa R, Graziadio C. Combined chemotherapy and teratogenicity. Birth Defects Res A Clin Mol Teratol 2005;73(9):634-7.
33. Yang D, Hladnik L. Treatment of acute promyelocytic leukemia during pregnancy. Pharmacotherapy 2009;29(6):709-24.
34. Siedner S, Kruger M, Schroeter M, Metzler D, Roell W, Fleischmann BK, et al. Developmental changes in contractility and sarcomeric proteins from the early embryonic to the adult stage in the mouse heart. J Physiol 2003;548(Pt 2):493-505.
35. Rudolph AM. Myocardial growth before and after birth: clinical implications. Acta Paediatr 2000;89(2):129-33.
36. Aviles A, Neri N, Nambo MJ. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann Oncol 2006;17(2):286-88.
37. Van Calsteren K, Berteloot P, Hanssens M, Vergote I, Amant F, Ganame J, et al. In utero exposure to chemotherapy: effect on cardiac and neurologic outcome. J Clin Oncol 2006;24(12):e16-7.
38. Witzel ID, Muller V, Harps E, Janicke F, Dewit M. Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 2008;19(1):191-2.
39. Warraich Q, Smith N. Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J Obstet Gynaecol 2009;29(2):147-8.
40. Shrim A, Garcia-Bournissen F, Maxwell C, Farine D, Koren G. Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy--Case report and updated literature review. Reprod Toxicol 2007;23(4):611-3.
41. Beale JM, Tuohy J, McDowell SJ. Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol 2009;201(1):e13-4.
42. Bader AA, Schlembach D, Tamussino KF, Pristauz G, Petru E. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 2007;8(1):79-81.
43. Goodyer MJ, Ismail JR, O'Reilly SP, Moylan EJ, Ryan CA, Hughes PA, et al. Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J 2009;2:9329.
44. Azim HA, Jr., Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 2010;6(6):821-6.
45. Mandrawa CL, Stewart J, Fabinyi GC, Walker SP. A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust N Z J Obstet Gynaecol 2011;51(4):372-6.
46. Huhta JC, Paul JJ. Doppler in fetal heart failure. Clin Obstet Gynecol 2010;53(4):915-29.
47. Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004;15(1):146-50.
48. Achtari C, Hohlfeld P. Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy. Am J Obstet Gynecol 2000;183(2):511-2.
49. Reynoso EE, Huerta F. Acute leukemia and pregnancy--fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol 1994;33(6):709-10.
50. Baumgartner AK, Oberhoffer R, Jacobs VR, Ostermayer E, Menzel H, Voigt M, et al. Reversible foetal cerebral ventriculomegaly and cardiomyopathy under chemotherapy for maternal AML. Onkologie 2009;32(1-2):40-3.
51. Meyer-Wittkopf M, Barth H, Emons G, Schmidt S. Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature. Ultrasound Obstet Gynecol 2001;18(1):62-6.